Get the Stockscreener App
30.20
4.86%
1.40
Pre-market:
30.20
Sutro Biopharma Inc stock is traded at $30.20, with a volume of 188.64K.
It is up +4.86% in the last 24 hours and down -22.50% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$28.80
Open:
$29.285
24h Volume:
188.64K
Relative Volume:
0.71
Market Cap:
$500.43M
Revenue:
$99.61M
Net Income/Loss:
$-153.60M
P/E Ratio:
-1.8361
EPS:
-16.4479
Net Cash Flow:
$-152.14M
1W Performance:
+19.18%
1M Performance:
-22.50%
6M Performance:
+204.13%
1Y Performance:
+277.93%
1-Day Range:
$28.80
$30.72
1-Week Range:
$24.39
$30.72
52-Week Range:
$6.736
$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
30.20 | 500.43M | 99.61M | -153.60M | -152.14M | -16.45 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Initiated | Leerink Partners | Outperform |
| Mar-24-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-24-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-20-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
This drug 'gave our daughter another chance' — now a nonprofit's deal hopes to secure its use for years to come - The Business Journals
Sutro Biopharma (STRO) Surges Over 9% as Buyers Test Key Resistance at $30.54Elliott Wave Entry - newsline.com
Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities - Moomoo
Truist Financial Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo
Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director granted 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director awarded 10,000 stock options at $26.09 strike - Stock Titan
Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027 - Stock Titan
Sutro Biopharma (STRO) director receives 10,000-share stock option grant - Stock Titan
[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Sutro Biopharma (STRO) director receives grant of 10,000 stock options - Stock Titan
Director at Sutro Biopharma (STRO) receives 10,000 stock options as equity grant - Stock Titan
Sutro Biopharma (NASDAQ: STRO) reports 2026 annual meeting results - Stock Titan
Sutro Biopharma Surges 5.52% – Testing Key Resistance at $30.11 After Strong SessionAdvance Decline Volume - newsline.com
Sutro Biopharma (STRO) CFO exercises 2,500 RSUs and increases direct holdings - Stock Titan
STRO Q1 2026 Earnings: Narrower Loss Beats Estimates as Sutro Biopharma Advances PipelineTech Earnings Analysis - The Legal Advocate
Barclays Initiates a Buy Rating on Sutro Biopharma (STRO) - The Globe and Mail
STRO Initiated Coverage by Barclays -- Rating Set to Overweight - GuruFocus
Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target - marketscreener.com
Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts By 46% - simplywall.st
News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts - Yahoo Finance
Barclays initiates Sutro Biopharma stock with overweight rating By Investing.com - Investing.com Australia
Barclays initiates Sutro Biopharma stock with overweight rating - Investing.com
Sutro Biopharma (STRO) Surges 6%: Key Levels and Market DynamicsEarnings Beat Stocks - The Legal Advocate
H.C. Wainwright Remains a Buy on Sutro Biopharma (STRO) - The Globe and Mail
H.C. Wainwright Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Sutro Biopharma CEO unveils expanding ADC pipeline and key cancer partnerships - Traders Union
Sutro Biopharma (STRO) price target increased by 1,325.54% to 39.05 - MSN
Sutro Biopharma (STRO) Consolidates Near Resistance: Biotech Stock Shows Modest GainsSocial Trading Insights - Newser
Sutro Biopharma (STRO) Sees Minor Dip, Holds Above Key SupportWyckoff Accumulation - Newser
STRO SEC FilingsSutro Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
US$47.10That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results - Yahoo Finance
Update: Sutro Biopharma Shares Rise After Q1 Loss Narrows - Moomoo
STRO Maintained by HC Wainwright & Co. -- Price Target Raised to $50 - GuruFocus
STRO Upgraded by Wedbush -- Price Target Raised to $60 - GuruFocus
Is Sutro Biopharma (STRO) 189.6% Overvalued After Q1 2026? EPS b - GuruFocus
Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 14% Upside - TradingView
Sutro Biopharma (STRO) affiliates disclose 1.06M shares; ownership details - Stock Titan
Kynam Capital reports 5.27% stake in Sutro Biopharma (NASDAQ: STRO) - Stock Titan
STRO Maintained by Leerink Partners -- Price Target Raised to $4 - GuruFocus
Sutro Biopharma Shares Rise After Q1 Loss Narrows - marketscreener.com
Gemini Space posts upbeat Q1 results, joins Figma, Sutro Biopharma and other big stocks moving higher on Friday - MSN
Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22 - Moomoo
Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday - Benzinga
Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $41.64, Implies 8% Upside - TradingView
Sutro Biopharma (STRO) Q1 Revenue Surpasses Expectations - GuruFocus
Sutro Biopharma Q1 Loss Narrows, Revenue Declines - Moomoo
Sutro Biopharma (NASDAQ: STRO) narrows Q1 loss and boosts cash with $110M share sale - Stock Titan
Sutro Biopharma releases first quarter financials and updates business outlook - Traders Union
Net loss narrows as Sutro Biopharma (NASDAQ: STRO) boosts cash into 2028 - Stock Titan
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 04 '26 |
Option Exercise |
0.00 |
675 |
0 |
10,025 |
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):